BioCryst Pharmaceuticals | BCRX - Equity Capital And Reserves


BioCryst Pharmaceuticals reported $-387.89M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
Chugai Pharma JPY 1.89T 95.02B Sep/2025
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
DBV Technologies USD 52.85M 33.37M Sep/2025
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Glaxosmithkline GBP 21.7B 7.35B Sep/2025
Incyte USD 5.17B 516.28M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Karyopharm Therapeutics USD -269.26M 30.33M Sep/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Novavax USD -156.67M 194.3M Sep/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025